| Phase 110 trials |
|
Phase 1
|
NCT07796191 |
Sep → Nov 2026 expected |
— |
Jiangsu vcare pharmaceutical technology co., LTD |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07551570 |
May → Oct 2026 expected |
impaired renal function disease |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07551557 |
Apr → Oct 2026 expected |
— |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07533851 |
Apr 2026 |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07329101 |
Nov 2025 → Feb 2026 |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06974292 |
May → Jun 2025 |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06009094 |
Jul 2023 → May 2024 |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05874622 |
Jun → Oct 2023 |
rheumatoid arthritis |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05354752 |
Jun → Nov 2022 |
inflammatory bowel disease |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05138770 |
Nov 2021 → Aug 2022 |
inflammatory bowel disease |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT07828639 |
Sep 2026 → May 2027 expected |
vitiligo |
Jiangsu vcare pharmaceutical technology co., LTD |
Not yet recruiting
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT07598383 |
Jun 2026 → Feb 2027 expected |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07172347 |
Oct 2025 → Aug 2027 expected |
vitiligo |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06891040 |
Apr → Oct 2025 |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05814939 |
Apr 2023 → May 2024 |
ankylosing spondylitis |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07592585 |
May 2026 → May 2028 expected |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07172360 |
Dec 2025 → Aug 2027 expected |
ankylosing spondylitis |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06723080 |
Dec 2024 → Aug 2027 expected |
atopic eczema |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|